{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:04:08Z","timestamp":1785290648345,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.det.2024.02.013","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T04:20:06Z","timestamp":1712204406000},"page":"357-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oral Psoriasis Therapies"],"prefix":"10.1016","volume":"42","author":[{"given":"JaBreia","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.det.2024.02.013_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/toxsci\/kfr184","article-title":"Arsenic exposure and toxicology: A historical perspective","volume":"123","author":"Hughes","year":"2011","journal-title":"Toxicol Sci"},{"issue":"1","key":"10.1016\/j.det.2024.02.013_bib2","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2020.1729951","article-title":"United States systemic psoriasis treatments: increases in the use of biologic agents and plateau of methotrexate and oral small molecule inhibitors","volume":"33","author":"Muddasani","year":"2022","journal-title":"J\u00a0Dermatol Treat"},{"issue":"4","key":"10.1016\/j.det.2024.02.013_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s00403-018-1808-x","article-title":"Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review","volume":"310","author":"Florek","year":"2018","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"10.1016\/j.det.2024.02.013_bib4","article-title":"Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States","volume":"4","author":"Feldman","year":"2016","journal-title":"J\u00a0Health Econ Outcomes Res"},{"issue":"6","key":"10.1016\/j.det.2024.02.013_bib5","article-title":"A\u00a0discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients in Japan","volume":"50","author":"Komine","year":"2023","journal-title":"J\u00a0Dermatol (Tokyo)"},{"key":"10.1016\/j.det.2024.02.013_bib6","doi-asserted-by":"crossref","DOI":"10.2147\/PPA.S242336","article-title":"Treatment mode preferences in psoriatic arthritis: A qualitative multi-country study","volume":"14","author":"Aletaha","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"10.1016\/j.det.2024.02.013_bib7","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/bjd.17587","article-title":"British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018","volume":"180","author":"Berth-Jones","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.02.013_bib8","author":"Bolognia"},{"issue":"5","key":"10.1016\/j.det.2024.02.013_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153740","article-title":"Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials","volume":"11","author":"West","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.det.2024.02.013_bib10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.det.2024.02.013_bib11","article-title":"Systemic methotrexate for the treatment of psoriasis","volume":"11","author":"Y\u00e9lamos","year":"2015","journal-title":"Expet Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.det.2024.02.013_bib12","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2133.1998.02319.x","article-title":"A\u00a0randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis","volume":"139","author":"Koo","year":"1998","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.013_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2133.1994.tb02935.x","article-title":"Efficacy and safety of oral cyclosporin A (CyA; Sandimmun\u00ae) for long-term treatment of chronic severe plaque psoriasis","volume":"130","author":"LABURTE","year":"1994","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.013_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/0190-9622(92)70012-5","article-title":"participants in the German multicenter study. Cyclosporine in psoriasis: A multicenter dose-finding study in severe plaque psoriasis","volume":"26","author":"Christophers","year":"1992","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.013_bib15","doi-asserted-by":"crossref","DOI":"10.2340\/0001555577137141","article-title":"Low-dose (1.25 mg\/kg) cyclosporin A: Treatment of psoriasis and investigation of the influence on lipid profile","volume":"77","author":"Meffert","year":"1997","journal-title":"Acta Derm Venereol"},{"issue":"SUPPL. 2","key":"10.1016\/j.det.2024.02.013_bib16","article-title":"Oral cyclosporin in psoriasis: A systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis","volume":"25","author":"Maza","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2024.02.013_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/S0190-9622(88)70198-X","article-title":"Acitretin versus etretinate in psoriasis: Clinical and pharmacokinetic results of a German multicenter study","volume":"19","author":"Gollnick","year":"1988","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.013_bib18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1067\/mjd.2001.116347","article-title":"Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis","volume":"45","author":"Lebwohl","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.013_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.14349","article-title":"Long-term safety and drug survival of acitretin in psoriasis: a retrospective observational study","volume":"58","author":"Chularojanamontri","year":"2019","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.013_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-3083.2012.04644.x","article-title":"Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: A randomized, double blind, parallel group, dose ranging study","volume":"27","author":"Dogra","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.det.2024.02.013_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in\u00a0vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.det.2024.02.013_bib22","first-page":"177","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in a tertiary-referral psoriasis service","author":"Foulkes","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.013_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9843","key":"10.1016\/j.det.2024.02.013_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.det.2024.02.013_bib25","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.140647","article-title":"Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis","volume":"42","author":"Kavanaugh","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.013_bib26","article-title":"Use of apremilast for the treatment of plaque psoriasis in a real world setting. The experience of a reference hospital in the Canary Islands","volume":"81","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.013_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for \u2265156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.02.013_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.det.2024.02.013_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.det.2024.02.013_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1\/2\/3 Inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther"},{"issue":"17","key":"10.1016\/j.det.2024.02.013_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.det.2024.02.013_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.013_bib33","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J\u00a0Inflamm"},{"issue":"4","key":"10.1016\/j.det.2024.02.013_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.det.2024.02.013_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"19","key":"10.1016\/j.det.2024.02.013_bib36","article-title":"Role of janus kinase inhibitors in therapy of psoriasis","volume":"10","author":"S\u0142uczanowska-G\u0142abowska","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.det.2024.02.013_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases","volume":"33","author":"Virtanen A","year":"2019","journal-title":"BioDrugs"},{"issue":"5","key":"10.1016\/j.det.2024.02.013_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br J Dermatol"},{"issue":"14","key":"10.1016\/j.det.2024.02.013_bib39","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.det.2024.02.013_bib40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"N\u00a0Engl J Med"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T17:07:01Z","timestamp":1731690421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0733863524000263"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.02.013","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Psoriasis Therapies","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}